Description: Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after dropping 6.9% in the last month, and are down 19.1% year-to-date. Recently, the stock has moved in response to industry-wide buzz around new diabetes technology and updates from competitors that are reshaping investor sentiment. Headlines have highlighted both innovation and competitive...

Description: DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting improved accuracy and convenience for diabetes management in adults. These product advancements arrive as DexCom faces multiple class action lawsuits and regulatory scrutiny related to alleged unauthorized design changes in its G6 and G7 devices, raising questions about reliability and company...

Description: Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. U.S. large-cap growth equities continued to recover from a sharp sell-off in early April. Strong corporate earnings, investor enthusiasm around artificial intelligence (AI), and growing expectations for Federal Reserve […]

Description: Pre-Market Stock Futures: The futures are lower on Tuesday after traders kicked off the holiday-shortened trading week with a massive Monday rally, with all major indices finishing the day higher. A combination of an oversold market, a big bounce-back rally on Friday that saw follow-through on Monday, and some positive AI/Data Center/Hyperscaler commentary to help ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, Serv

Description: Del Mar, California--(Newsfile Corp. - November 25, 2025) - American Diversified Holdings Corporation (OTCID: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a).The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and...

Description: DexCom Inc. (NASDAQ:DXCM) is one of the best QQQ stocks to buy according to Wall Street analysts. On November 10, Morgan Stanley cut the price target on DexCom to $63 from $89, while maintaining an Overweight rating on the shares. Additionally, on November 3, Truist also lowered the firm’s price target on DexCom to $82 […]

Description: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continued their rally, fueled by enthusiasm for AI, limited evidence of inflationary effects from tariffs, and expectations for further interest […]

Description: A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.

Description: If you're investing for the next 30 years, don't overlook these top stocks.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: These healthcare stocks have long-term and profitable growth runways.

Description: DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This notable step forward signals a new phase for the company. See our latest analysis for DexCom. While the FDA clearance for Smart Basal is a milestone, DexCom’s recent stock performance has yet to reflect renewed optimism. The share price sits at $59.73 after a one-year total shareholder return of...

Description: DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.

Description: SAN DIEGO, November 20, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM s

Description: The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For

Description: SAN DIEGO, November 19, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as

Description: DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven by a modest increase in the discount rate and more cautious revenue growth projections. The revision reflects tempered optimism following the company's latest guidance and earnings results. Stay tuned to learn how you can stay informed on future updates and shifts in DexCom's valuation narrative...

Description: Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […]

Description: SAN DIEGO, November 14, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom’s World Diabetes Day campaign.

Description: Insightful Analysis of Frank Sands (Trades, Portfolio)' Third Quarter 2025 13F Filing

Description: Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.

Description: Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices, resulting in potential reliability and safety issues and prompting regulatory scrutiny, including a warning letter from the FDA. This legal and regulatory attention grew after reports linked the device changes to health risks, hospitalizations, and deaths, prompting intensified market...

Description: Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Description: Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen mixed momentum lately, climbing just 0.6% over the past week but still down 24.1% year-to-date and 17.8% in the past twelve months. This performance has put value-focused investors on alert. Recent news around DexCom's continued innovation in glucose monitoring technology has kept the company in...

Description: Founder and Chief Executive Officer Will Ahmed said the business is well-positioned for an IPO now that it’s broadened its portfolio to include proprietary technology, hardware, software, analytics and other items, such as accessories and apparel. While Ahmed has previously said Whoop is likely to go public, he hadn’t shared when that might happen. “We like to build things ourselves and we really want to build this home of health for our members,” he added.

Description: In the past week or so, renowned investors Carl Icahn and Mario Gabelli led some huge insider buying. These were not the only notable purchases though.

Description: Carrot today announced a partnership with ŌURA, the world's leading smart ring, and Dexcom, the global leader in glucose biosensing, to empower members with actionable, personalized insights that support fertility and family-building goals through the metabolic-fertility program, Sprints. This collaboration combines Carrot's clinical expertise with advanced insights from ŌURA and Stelo by Dexcom, the first FDA-cleared glucose biosensor available without a prescription in the United States, empow

Description: DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Description: Shares are near their lowest levels in five years.

Description: The global patient monitoring devices market size is expected to reach USD 118.21 billion by 2033, registering a CAGR of 10.21% from 2025 to 2033, according to a new report by Grand View Research, Inc. This expansion is fundamentally driven by the increasing need to measure and display vital biometric data. This demand stems from three primary factors: the growing geriatric population and rising prevalence of chronic conditions like cardiovascular disease and diabetes, which require continuous m

Description: MONTREAL, November 07, 2025--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l’assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*.

Description: DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could potentially impact their reliability and safety. See our latest analysis for DexCom. DexCom’s recent tumble, including a 13% share price drop over the past week and a 24% year-to-date decline, follows mounting legal challenges and persistent questions about product reliability. Even with strong...

Description: The stock was sluggish on the back of DexCom, Inc.'s ( NASDAQ:DXCM ) recent earnings report. We have done some...

Description: DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS expectations. Management attributed quarterly growth to increased continuous glucose monitoring (CGM) adoption among people with type 2 diabetes, particularly following expanded insurance coverage and deeper reach into primary care. Interim CEO Jacob Leach emphasized the impact of new product features and improved access, but also acknowledged lingering manufacturing and sensor

Description: The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance and delivering strong returns.

Description: The Dow Jones index fell but Amazon surged on deal with OpenAI. Kimberly-Clark plunged on the stock market today. Palantir popped.

Description: Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The stock had previously plunged more than 14% after the company's interim CEO stated during its third-quarter earnings call that revenue growth for 2026 could fall short of analyst expectations. This cautious forecast overshadowed an otherwise strong report, in which the company beat third-quarter earnings

Description: As the United States stock market experiences a period of gains with major indices like the Nasdaq, S&P 500, and Dow Jones Industrial Average posting solid weekly and monthly increases, investors are keenly observing opportunities that may be priced below their intrinsic value. In such an environment, identifying stocks that appear undervalued can be crucial for those looking to capitalize on potential market inefficiencies and enhance portfolio performance.

Description: As of the end of October 2025, U.S. stock markets have shown resilience, with major indices like the Nasdaq, S&P 500, and Dow Jones Industrial Average posting solid gains for both the week and month. In this environment of growth and recovery, identifying stocks that may be trading below their estimated value can present opportunities for investors seeking to capitalize on potential market inefficiencies.

Description: DexCom (DXCM) is forecasting robust earnings growth of 19.2% per year and revenue growth of 11.8% per year. Both figures outpace the broader US market’s revenue growth forecast of 10.4%. Over the past five years, earnings have grown at an annual rate of 10.9%, but the most recent net profit margin declined to 13.3% from 16.9% a year earlier. With no major risks flagged and solid projections for both profits and revenues, the stage is set for positive investor sentiment around DexCom’s latest...

Description: In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o

Description: The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a soft sales outlook weighed on a medical device firm's stock.

Description: Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 6% in the afternoon session after investor concerns were sparked by a disappointing financial outlook from peer DexCom. DexCom, a major company in the glucose monitoring market, reported its third-quarter financial results. Although the company's earnings and revenue surpassed targets, its stock fell sharply by around 11% to 12%. The drop was triggered after company executives provided a growth forecast for 2026 that m

Description: US equity indexes closed higher on Friday, bolstered by a surge in Amazon.com's (AMZN) shares follow

Description: iPhone maker Apple and cloud-computing and online retailing giant Amazon post better-than-expected earnings.

Description: Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

Description: DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.

Description: Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings.

Description: DexCom (DXCM) shares fell nearly 15% in recent Friday trading after multiple brokerages trimmed thei

Description: The diabetes equipment provider had a strong quarter, but next year is looking weaker than expected.

Description: DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from concerns over slower-than-expected growth. Interim CEO Jake Leach indicated on DexCom’s third-quarter earnings call Thursday that 2026 revenue growth could miss analysts’ forecasts. While growth is expected to be “certainly in that double-digit range,” Leach said, “the top end of our range is probably slightly below where the Street is today for our base case.”

Description: Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.

Description: After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer service has also been a focus for the company.

Description: DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market advancements.

Description: Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: DexCom (DXCM) delivered earnings and revenue surprises of +7.02% and +2.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.

Description: The San Diego-based company said it had net income of 70 cents per share. Earnings, adjusted for non-recurring gains, were 61 cents per share. The results surpassed Wall Street expectations.

Description: SAN DIEGO, October 30, 2025--Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

Description: DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 with a Buy rating on the shares as part of the firm’s broader research note previewing Q3 2025 results […]

Description: The company hasn't had a great year. Is it about to turn things around?

Description: Thinking about buying or holding DexCom stock? You’re not alone. Whether you’re a long-term investor or just looking for a timely healthcare pick, DexCom probably caught your attention for its role in continuous glucose monitoring, but its recent price moves might have you wondering if now is the best time to act. Shares closed at $69.23 recently, and the ride has been anything but smooth. In the past seven days, the stock slipped by 0.7%, recovering 3.2% over the last month. Yet DexCom still...

Description: Beyond analysts' top-and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Description: Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know.

Description: Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the

Description: DexCom (DXCM) shares were down over 2% in recent Tuesday trading after Hunterbrook issued a report a

Description: DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.

Description: ViCentra, a European medical device company redefining insulin delivery for people with diabetes with the Kaleido insulin patch pump system, today announced two strategic senior leadership appointments following the company's recent $85 million Series D financing. Karen Baxter, former Vice President & General Manager at Dexcom, joins as Senior Vice President of Sales, Europe, and Jay Little, a long-time commercialization and market access executive at Medtronic Diabetes, takes on the newly creat

Description: SAN DIEGO, October 27, 2025--Dexcom Appoints Euan Ashley to Board of Directors

Description: DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $65.41 as of October 15th. DXCM’s trailing and forward P/E were 46.79 and 25.64 respectively according to Yahoo Finance. Hunterbrook Media’s investigation reveals severe safety, operational, and financial concerns at […]

Description: Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "DexCom Inc (DXCM) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This analytical report serves as a pivotal resource for detailed insights into Dexcom's expansive pipeline, fostering robust data-driven decision-making and strategic competitive positioning. It offers comprehensive intelligence on Dexcom's portfolio, pivotal products, and emerging brands. Report Scope: Comprehensive company profile analy

Description: Investing.com -- Stifel has resumed coverage of several medtech companies, citing steady adoption of continuous glucose monitors (CGMs) and insulin pumps as key drivers for growth.